Tucidinostat - HUYA Bioscience International

Drug Profile

Tucidinostat - HUYA Bioscience International

Alternative Names: Chidamide; CS-055; Epidaza; HBI-8000

Latest Information Update: 28 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chipscreen Biosciences
  • Developer Chipscreen Biosciences; GNT Biotech and Medicals Corporation; Guangxi Center for Disease Control and Prevention; HUYA Bioscience International; IQVIA; Zhejiang University
  • Class Aminopyridines; Antineoplastics; Benzamides; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; HDAC1 protein inhibitors; HDAC10-protein-inhibitors; HDAC2 protein inhibitors; HDAC3 protein inhibitors; Mitogen-activated protein kinase inhibitors; Proto oncogene protein c-akt inhibitors; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase III Breast cancer
  • Phase II/III Cutaneous T cell lymphoma; HIV infections
  • Phase II Adult T-cell leukaemia-lymphoma; Non-small cell lung cancer
  • Phase I/II Solid tumours
  • No development reported Non-Hodgkin's lymphoma

Most Recent Events

  • 28 Sep 2018 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Late-stage disease) in Japan (PO)
  • 10 Jul 2018 Shenzhen Chipscreen Biosciences plans a phase II trial for Peripheral T-cell Lymphoma in China , (ChiCTR1800017061)
  • 25 Jun 2018 Taiwan Specialty Pharma in-licenses sales and marketing rights for tucidinostat from GNT Biotech and Medicals Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top